Imutec Corp. regulatory update

IMUTF completed development and validation of a new potency bioassay for Virulizin, an immunotherapeutic drug to treat cancer, and is preparing to file the necessary regulatory documentation to restart its clinical trial program in Canada and the U.S. Last October, the Toronto company delayed the trials pending the development and validation of a reliable assay for the drug (see BioCentury Oct. 17, 1994). ...